TY  - GEN
N2  - Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
DO  - 10.1007/978-3-030-74028-3
DO  - doi
AB  - Lung cancer has seen a paradigm shift in disease treatment over the past few years, with major changes in the therapeutic drugs now available as well as in the overall management approach. For targeted and immunotherapeutic approaches, understanding the biology of acquired resistance is a key strategy that has yielded productive advances in the subsequent treatment. Future advances also include incorporating biomarker data obtained from solid and liquid biopsies, as well as combination of immunotherapy with radiotherapy and in special populations such patients with CNS involvement.
T1  - Lung cancer :new understandings and therapies /
AU  - Chiang, Anne C.,
AU  - Herbst, Roy,
CN  - RC280.L8
N1  - Includes index.
ID  - 1440164
KW  - Lungs
KW  - Lungs
KW  - Poumons
KW  - Poumons
SN  - 9783030740283
SN  - 3030740285
TI  - Lung cancer :new understandings and therapies /
LK  - https://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-74028-3
UR  - https://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-74028-3
ER  -